885 reports of this reaction
7.4% of all LUMACAFTOR AND IVACAFTOR reports
#2 most reported adverse reaction
HOSPITALISATION is the #2 most commonly reported adverse reaction for LUMACAFTOR AND IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 885 FDA adverse event reports linking LUMACAFTOR AND IVACAFTOR to HOSPITALISATION. This represents approximately 7.4% of all 12,020 adverse event reports for this drug.
Patients taking LUMACAFTOR AND IVACAFTOR who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is moderately reported among LUMACAFTOR AND IVACAFTOR users, representing a notable but not dominant share of adverse events.
In addition to hospitalisation, the following adverse reactions have been reported for LUMACAFTOR AND IVACAFTOR:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 885 FDA reports for LUMACAFTOR AND IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 7.4% of all adverse event reports for LUMACAFTOR AND IVACAFTOR, making it one of the most commonly reported side effect.
If you experience hospitalisation while taking LUMACAFTOR AND IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.